Current Clinical Trials

For information or enquiries on the clinical trials listed below, please email clinical.trials@nccs.com.sg

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	NSCLC lung, PDAC / pancreatic and GC (GI)	Advanced recurrent	EBC-129-01 A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours	Dr Matthew Ng	NCT05701527	Open
2	NSCLC / lung, all solid tumours	locally advanced or metastatic / stage 4 / stage IV	NVL-520-01 A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)	Dr Daniel Tan	NCT05118789	Open
3	NSCLC / lung, all solid tumours	Advanced recurrent	NVL-655-01 A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Dr Aaron Tan	NCT05384626	Open
4	Ovarian, lung, breast, endometrial	Advanced, Metastatic / stage 4 / stage IV	PMV-586-101 A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)	Dr Tira Tan	NCT04585750	Open
5	Ovarian, Endometrial and Lung adenocarcinoma	Advanced, Metastatic / stage 4 / stage IV	ZWI-ZW191-101 A Phase 1, Open-label, Multicenter, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of a Novel Folate Receptor Alpha Inhibitor, ZW191, as Monotherapy in Participants with Advanced Solid Tumors	Dr Daniel Tan	NCT06555744	Open
6	Squamous Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer	Advanced, Metastatic / stage 4 / stage IV	ALE.P02.01 A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with selected CLDN1+ solid tumors	Dr Darren Lim	NCT06747585	Open
7	all solid tumours	Advanced, Metastatic / stage 4 / stage IV	BAYER 22931 A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors.	Dr David Tai	NCT06914128	Open
8	CRC, PDAC, NSCLC, other solid tumours	Advanced, Metastatic / stage 4 / stage IV	GO45416 A PHASE I/II DOSE-ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-7035 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED SOLID TUMORS WITH A KRAS G12D MUTATION	Dr David Tai	NCT06619587	Open
9	all solid tumors	Advanced, Metastatic / stage 4 / stage IV	YO45758 A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activitiy of RO7673396 as a Single Agent and in Combination with Other Anticancer Therapies in patients with Advanced Solid Tumors Harboring Ras Mutation(s)	Dr David Tai	NCT06884618	Open
10	NSCLC / Lung	Advanced, Metastatic / stage 4 / stage IV	BH-30643-01 A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)	Dr Darren Lim	NCT06706076	Open
11	Colorectal Cancer Intrahepatic Cholangiocarcinoma Urothelial Carcinoma Squamous Non-small Cell Lung Cancer Squamous Cervical Cancer	Advanced, Metastatic / stage 4 / stage IV	ALE.P03.01 A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with selected Advanced or Metastatic CLDN1+ solid tumors.	Dr David Tai	NCT07169734	Open
12	Breast, Gastric, Other solid tumor with HER2 amp	Advanced, Metastatic / stage 4 / stage IV	IKS014-01 A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors	Dr Tira Tan	NCT05872295	Open
13	all solid tumours	Advanced, Metastatic / stage 4 / stage IV	GO44431 A PHASE I, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7566802 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS	Dr Sophia Wong	NCT06031441	On hold
14	HR+ HER2- lobular BC, HR+ HER2- ductal BC, NSCLC, TNBC, CRC and soft tissue sarcoma	Advanced, Metastatic / stage 4 / stage IV	CGCJ904A12101 Phase I FIH dose escalation/expansion study to evaluate GCJ904 ([177Lu]Lu-DFC413), a radioligand therapy targeting FAP, as a single agent in multiple indications	Dr Aaron Tan	NCT07261631	Open
15	breast all solid tumors	Advanced, Metastatic / stage 4 / stage IV	CGVV858A12101 An open-label, multi-center, phase I/II study of CDK inhibitors as a single agent and in combination with endocrine therapy in patients with advanced HR+HER2- breast cancer and other advanced solid tumors	Dr Tira Tan	NCT07288359	Open
16	Colon	Advanced, Metastatic / stage 4 / stage IV	BAY 23111-1 An open-label multi-cohort study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BAY 3771249 as monotherapy and in combination with cetuximab in participants with metastatic colorectal adenocarcinoma harboring a KRAS G12D mutation	Dr David Tai	NCT07535112	Open
17	Urothelial, biliary tract, Uterine, cervical, non-sqamous NSCLC, salivary gland, colorectal, all solid tumors excep for breast	Advanced, Metastatic / stage 4 / stage IV	Beamion PANTUMOR-1 A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours	Dr Tira Tan	NCT06581432	Open
18	NSCLC / Lung	Mets NSCLC	HMBD-001-103 A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers	Dr Aaron Tan	NCT05910827	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Pancreas / GI/ BTC	Metastatic	D9800C00001/CLARITY-PanTumour01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)	Dr Matthew Ng	NCT06219941	On hold
2	Breast	Mets ER+PR+	ELEVATE A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive, HER2 negative breast cancer, who have progressed on CDK4/6 inhibitors	Dr Elaine Lim	NCT05181033	Open
3	Breast	PD-L1 Positive Locally Recurrent Inoperable or Metastatic TNBC	TROPION-Breast05: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast	Dr Rebecca Dent	NCT06103864	Open
4	Breast	HR-low+/HER2-, TROP2, and PD-L1 status	MK2870-032 A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer	Dr Tira Tan	NCT06966700	Open
5	Breast	Recurrence while on adjuvant ET ≥24mos	MK5684-015 A Multicenter, Open-label, Phase 2 Basket Study of MK 5684 in Participants With Selected Solid Tumors Cohort A – Breast Cancer	Dr Jack Chan	NCT06979596	Open
6	Breast	metastatic breast cancer	ASPEN-09-03 (Substudy Protocol) A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer Cancer	Dr Rebecca Dent	NCT07007559 Substudy 3	Open
7	Colorectal	locally advanced unreseectable/ Metastatic	KANDLELIT-012 A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer	Dr Dawn Chong	NCT06997497	Open
8	Colorectal	unreseectable/ Metastatic	CA266-0003 A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer	Dr Evelyn Wong	NCT07221357	On hold
9	Endometrial	pMMR and p53wt	MK5684-015 A Multicenter, Open-label, Phase 2 Basket Study of MK 5684 in Participants With Selected Solid Tumors Cohort C – Endometrial Cancer	Dr Jack Chan	NCT06979596	Open
10	Endometrial	Recurrent	BNT323-01 A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer	Dr Chay Wen Yee	NCT06340568	Open
11	HNSCC	recurrent, metastatic	BCA101X301 FORITFI-HN01 A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Dr Darren Lim	NCT06788990	Open
12	Liver cancer or Colorectal cancer with liver metastases / GI	Adjuvant	CA209-7R9 An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)	Dr Koo Si Lin	NCT04912765	Open
13	Liver / GI	Resectable HCC (high risk of recurrence)	AHCC12 Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)	Dr Toh Han Chong	NCT05516628	Open
14	Liver / GI	HCC, solid tumor with liver disease	Histotripsy Ablation for Liver Tumours (HALT): A Multi-centre Prospective Pilot Study on the Safety and Efficacy of Histotripsy in Asian Primary and Secondary Liver Malignancies	Dr Brian Goh	NCT07428356	Open
15	NSCLC / Lung	Mets NSCLC	LUNAR-2 EF-44 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer	Dr Ng Quan Sing	NCT06216301	Open
16	NSCLC / Lung	II to IIIB (N2) NSCLC	V940-009 A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)	Dr Aaron Tan	NCT06623422	Open
17	NSCLC / Lung	Mets NSCLC	IOV-LUN-202 A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145)in Patients with Metastatic Non-Small-Cell Lung Cancer	Dr Sophia Wong	NCT04614103	Open
18	NSCLC / Lung	Mets NSCLC	M25-274 A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Dr Gillianne Lai	NCT06568939	Open
19	NSCLC / Lung	Locally Advanced/ Mets NSCLC	D516KC00001 A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)	Dr Tan Wan Ling	NCT06417814	Open
20	NSCLC/Lung	Locally Advanced/ Mets NSCLC	NVL655-04 A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)	Dr Gillianne Lai	NCT06765109	Open
21	NSCLC/Lung	Locally Advanced/ Mets NSCLC	CO45042 A Phase III, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of Divarasib And Pembrolizumab Versus Pembrolizumab And Pemetrexed And Carboplatin Or Cisplatin In Patients With Previously Untreated, KRAS G12C-Mutated, Advanced Or Metastatic Non-Squamous Non−Small Cell Lung Cancer	Dr Gillianne Lai	NCT06793215	Open
22	NSCLC/Lung	Locally Advanced/ Mets NSCLC	M25-287 Non-Small Cell Lung Cancer: Telisotuzumab Adizutecan and Osimertinib Phase 2/3 Study in Previously Untreated Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation	Dr Stephanie Saw	NCT07005102	Open
23	NSCLC/Lung	Locally Advanced/ Mets NSCLC	RMC-6236-301 Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (RASolve 301)	Dr Amit Jain	NCT06881784	Open
24	NSCLC/Lung	Locally Advanced/ Mets NSCLC	D6187C00001 A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)	Dr Daniel Tan	NCT07098338	Open
25	NSCLC/Lung	Locally Advanced/ Mets NSCLC	ARR-630-301 A Global, Phase 3, Randomized, Multicenter, Open Label Study To Evaluate The Efficacy And Safety Of Firmonertinib Compared With Osimertinib As Firstline Treatment In Participants Who Have Locally Advanced Or Metastatic Non-small-cell Lung Cancer With Epidermal Growth Factor Receptor P-loop And Alpha C-helix Compressing (PACC) Mutations (FURMO-006)	Dr Gillianne Lai	NCT07185997	Open
26	NSCLC/Lung	resectable NSCLC (stage II-IIIA)	1479-0032 Beamion LUNG-3: A randomized, controlled study of zongertinib as a monotherapy compared to standard of care in patients with resectable NSCLC (stage II-IIIA) and activating HER2 mutations	Dr Stephanie Saw	NCT07195695	Open
27	SCLC / Lung	extensive-stage small cell lung cancer	1438-0012 A Phase III multi-center, open-label, randomized trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs atezolizumab, carboplatin, and etoposide as first line of treatment in patients with extensive-stage small cell lung cancer (DAREON-Lung-1)	Dr Amanda Seet	NCT07472517	Open
28	NSCLC/ Lung	Adjuvant NSCLC	TAS6417-302 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)	Dr Gilliane Lai	NCT07128199	Open
29	NSCLC / Lung	Locally Advanced/ Mets NSCLC	Bayer 22615 A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations	Dr Aaron Tan	NCT06452277	Open
30	SCLC / Lung	Extensive stage SCLC	CDJI136A12101 A Phase I/II Open Label Study of DJI136, a DLL3-targeted CAR-T therapy, in Adult Patients with ES-SCLC	Dr Sophia Wong	NCT07564401	Open
31	Lymphoma	relapsed/ refractory Lymphoma	POLAR Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)	Dr Lim Soon Thye	NCT06160843	Open
32	Lymphoma	untreated B-cell lymphoma	MK-2140-010 A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)	Dr Joshua Hoe	NCT06717347	On hold
33	Chronic Myeloid Leukemia	Chronic Phase	POLARIS-2 A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia	Dr Charles Chuah	NCT06423911	Open
34	Melanoma	Unresectable or metastatic	IOV-MEL-301 A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma	Dr Nagavalli	NCT05727904	Open
35	NPC	Metastatic, mets	SG-AAA-II-01 / CAAA601A0SG01T A Biomarker Enrichment Phase II study of 177Lu-DOTATATE in Metastatic Nasopharyngeal Cancer with a safety run-in	Dr Daniel Tan	NCT05198479	On hold
36	NPC	stage IIIA-IVA	RIBBON-LA-01 Single-arm, open-label, phase 2 trial of tislelizumab and metronomic capecitabine as maintenance therapy in high-risk locoregionally-advanced nasopharyngeal carcinoma	Dr Darren Lim	NCT06093061	Open
37	NPC	recurrent/metastatic	NRG-HN011 A randomized phase II study of nivolumab versus nivolumab and BMS-986016 (relatlimab) as maintenance treatment after first-line treatment with platinum-gemcitabine-nivolumab for patients with epstein-barr virus-associated recurrent/metastatic nasopharyngeal carcinoma (REMAIN)	Dr Darren Lim	NCT06029270	Open
38	Ovarian cancer	maintenance	[IIT] NIRVANA-1 A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery	Dr Jack Chan	NCT05183984	Open
39	Ovarian	advanced	MK5684-015 A Multicenter, Open-label, Phase 2 Basket Study of MK 5684 in Participants With Selected Solid Tumors Cohort B - Ovarian Cancer	Dr Jack Chan	NCT06979596	Open
40	Ovarian	maintenance	DS8201-772 A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer	Dr Soh Lay Tin	NCT06819007	Open
41	Pancreas / GI	Metastatic	LDOXIRI-PDAC-01 A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients	Dr Joycelyn Lee	NCT05929885	Open
42	Pancreas / GI	Metastatic	D9800C00001/CLARITY-PanTumour01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)	Dr Matthew Ng	NCT06219941	On hold
43	Pancreas / GI	Metastatic	CA240-0030 A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	Dr David Tai	NCT07076121	On hold
44	Prostate	Metastatic	CAAA617D12302 An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)	Dr Jeffery Tuan	NCT05939414	Open
45	Prostate	Metastatic/ mCRPC	MK-5684-003 A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Dr Ravindran Kanesvaran	NCT06136624	Open
46	Prostate	Metastatic/ mCRPC	MK5684-004 A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)	Dr Johan Chan	NCT06136650	On hold
47	Prostate	Metastatic/ mCRPC	CAAA817A12201 A phase II/III, open-label, international, multi-center, randomized study of AAA817 versus best standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy	Dr Ravindran Kanesvaran	NCT06780670	Open
48	Prostate	Metastatic/ mCRPC	CAAA817B12301 (AcTFirst) A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care inadult participants with PSMA-positive metastatic castration resistant prostate cancer	Dr Johan Chan	NCT06855277	Open
49	Prostate	Metastatic/ mCRPC	Amgen 20230239 A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Monotherapy, Xaluritamig Plus Abiraterone versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer	Dr Johan Chan	NCT07213674	Open
50	Prostate	Metastatic/ mCRPC	177Lu-TLX591-203 A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Receptor Pathway Inhibitor (ARPI) Treatment	Dr Ravindran Kanesvaran	NCT06520345	Open
51	Prostate	Metastatic/ mCRPC	MK-2400-001 A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)	Dr Johan Chan	NCT06925737	Open
52	Renal	Advanced/ Metastatic	MK6482-033 A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)	Dr Ravindran Kanesvaran	NCT07227402	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	APL10101 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Dr Gillianne Lai	NCT03175224	Open
2	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	TPX-0005-01 A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)	Dr Darren Lim	NCT03093116	Open
3	SOLID TUMORS	ADVANCED/ METASTATIC	Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations	Dr Joanne Ngeow	NCT04924075	Open